PRODUCT INFORMATION



CAY10602

Item No. 10009796

CAS Registry No.:	374922-43-7	
Formal Name:	1-(4-fluorophenyl)-3-(phenylsulfonyl)-1H-	
	pyrrolo[2,3-b]quinoxalin-2-amine	
MF:	$C_{22}H_{15}FN_4O_2S$	N NH ₂
FW:	418.4	
Purity:	≥95%	
UV/Vis.:	λ _{max} : 216, 257, 361 nm	
Supplied as:	A crystalline solid	\int
Storage:	-20°C	
Stability:	≥2 years	Ť
1 6 1		

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CAY10602 is supplied as a crystalline solid. A stock solution may be made by dissolving the CAY10602 in the solvent of choice, which should be purged with an inert gas. CAY10602 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of CAY10602 in these solvents is approximately 20 mg/ml.

CAY10602 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CAY10602 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. CAY10602 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

CAY10602 is an activator of sirtuin 1 (SIRT1).¹ It inhibits LPS-induced TNF- α release in THP-1 cells when used at concentrations of 20 and 60 μ M. CAY10602 (5 μ M) decreases the expression of GPX4, SLC7A11, and SLC3A2, as well as increases the levels of iron and malondialdehyde (MDA), in A549 lung and MDA-MB-231 and Hs 578T breast cancer cells.² It reduces apoptosis and lipid accumulation induced by oleic acid (Item Nos. 90260 | 24659) in HepG2 cells when used at a concentration of 20 μ M.³

References

- 1. Nayagam, V.M., Wang, X., Tan, Y.C., et al. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J. Biomol. Screen. 11(8), 959-967 (2006).
- 2. Sui, S., Zhang, J., Xu, S., et al. Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells. Cell Death Dis. 10, 331 (2019).
- 3. Jiang, Y., Chen, D., Gong, Q., et al. Elucidation of SIRT-1/PGC-1α-associated mitochondrial dysfunction and autophagy in nonalcoholic fatty liver disease. Lipids Health Dis. 20(1), 40 (2021).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/14/2021

F

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM